146 related articles for article (PubMed ID: 30927244)
1. Diabetes as a prognostic factor in HER-2 positive breast cancer patients treated with targeted therapy.
Lee A; Jo S; Lee C; Shin HH; Kim TH; Ahn KJ; Park SK; Cho H; Yoon HK; Kim WG; Park J; Choi Y
Breast Cancer; 2019 Sep; 26(5):672-680. PubMed ID: 30927244
[TBL] [Abstract][Full Text] [Related]
2. Association Between Targeted HER-2 Therapy and Breast Reconstruction Outcomes: A Propensity Score-Matched Analysis.
Shammas RL; Cho EH; Glener AD; Poveromo LP; Mundy LR; Greenup RA; Blackwell KL; Hollenbeck ST
J Am Coll Surg; 2017 Dec; 225(6):731-739.e1. PubMed ID: 28985927
[TBL] [Abstract][Full Text] [Related]
3. Prognostic value of phosphorylated HER2 in HER2-positive breast cancer patients treated with adjuvant trastuzumab.
Kurebayashi J; Kanomata N; Yamashita T; Shimo T; Mizutoh A; Moriya T; Sonoo H
Breast Cancer; 2015 May; 22(3):292-9. PubMed ID: 23749689
[TBL] [Abstract][Full Text] [Related]
4. Resumption of Trastuzumab in Patients With Disease Recurrence After (Neo-) Adjuvant Anti-HER2-therapy in Patients With HER2-positive Breast Cancer.
Hanker LC; FÖrster F; SchrÖder J; Grafe A; Hitschold T; Hesse T; Lattrich CR; Rody A
Anticancer Res; 2020 Jul; 40(7):3973-3981. PubMed ID: 32620640
[TBL] [Abstract][Full Text] [Related]
5. Tumor-infiltrating lymphocytes predict prognosis of breast cancer patients treated with anti-Her-2 therapy.
Chen TH; Zhang YC; Tan YT; An X; Xue C; Deng YF; Yang W; Yuan X; Shi YX
Oncotarget; 2017 Jan; 8(3):5219-5232. PubMed ID: 28029650
[TBL] [Abstract][Full Text] [Related]
6. Baseline Lymphopenia: A Predictor Of Poor Outcomes In HER2 positive Metastatic Breast Cancer Treated With Trastuzumab.
Che YQ; Zhang Y; Wang D; Liu HY; Shen D; Luo Y
Drug Des Devel Ther; 2019; 13():3727-3734. PubMed ID: 31754298
[TBL] [Abstract][Full Text] [Related]
7. Retrospective analysis of efficacy of trastuzumab in adjuvant treatment of HER 2 positive early breast cancer - single institution experience.
Ban M; Viculin J; Tomic S; Capkun V; Strikic A; Mise BP; Utrobicic I; Vrdoljak E
Neoplasma; 2016; 63(5):761-7. PubMed ID: 27468880
[TBL] [Abstract][Full Text] [Related]
8. tRNA-Derived Fragments as Novel Predictive Biomarkers for Trastuzumab-Resistant Breast Cancer.
Sun C; Yang F; Zhang Y; Chu J; Wang J; Wang Y; Zhang Y; Li J; Li Y; Fan R; Li W; Huang X; Wu H; Fu Z; Jiang Z; Yin Y
Cell Physiol Biochem; 2018; 49(2):419-431. PubMed ID: 30153663
[TBL] [Abstract][Full Text] [Related]
9. [Prognostic value of estrogen receptor, progesterone receptor and human epidermal growth factor receptor-2 in node positive breast cancer patients treated by mastectomy].
Wang SL; Li YX; Song YW; Wang WH; Jin J; Liu YP; Liu XF; Yu ZH
Zhonghua Zhong Liu Za Zhi; 2010 Jul; 32(7):520-5. PubMed ID: 21029696
[TBL] [Abstract][Full Text] [Related]
10. Roles of neutrophil/lymphocyte ratio in prognosis and in differentiation of potential beneficiaries in HER2-positive breast cancer with trastuzumab therapy.
Ding N; Huang J; Li N; Yuan J; Wang S; Xiao Z
BMC Cancer; 2020 Mar; 20(1):235. PubMed ID: 32192443
[TBL] [Abstract][Full Text] [Related]
11. CTMP, a predictive biomarker for trastuzumab resistance in HER2-enriched breast cancer patient.
Chen YC; Li HY; Liang JL; Ger LP; Chang HT; Hsiao M; Calkins MJ; Cheng HC; Chuang JH; Lu PJ
Oncotarget; 2017 May; 8(18):29699-29710. PubMed ID: 27447863
[TBL] [Abstract][Full Text] [Related]
12. Long-term survival in trastuzumab-treated patients with HER2-positive metastatic breast cancer: real-world outcomes and treatment patterns in a whole-of-population Australian cohort (2001-2016).
Daniels B; Kiely BE; Lord SJ; Houssami N; Lu CY; Ward RL; Pearson SA
Breast Cancer Res Treat; 2018 Aug; 171(1):151-159. PubMed ID: 29736743
[TBL] [Abstract][Full Text] [Related]
13. Effects of trastuzumab on locoregional recurrence in human epidermal growth factor receptor 2-overexpressing breast cancer patients treated with chemotherapy and radiotherapy.
Jeon SH; Shin KH; Kim JH; Kim K; Kim IA; Lee KH; Kim TY; Im SA
Breast Cancer Res Treat; 2018 Dec; 172(3):619-626. PubMed ID: 30209731
[TBL] [Abstract][Full Text] [Related]
14. Locoregional recurrence and survival outcomes by type of local therapy and trastuzumab use among women with node-negative, HER2-positive breast cancer.
Peterson DJ; Truong PT; Sadek BT; Alexander CS; Wiksyk B; Shenouda M; Raad RA; Taghian AG
Ann Surg Oncol; 2014 Oct; 21(11):3490-6. PubMed ID: 24841346
[TBL] [Abstract][Full Text] [Related]
15. Changing Natural History of HER2-Positive Breast Cancer Metastatic to the Brain in the Era of New Targeted Therapies.
Mounsey LA; Deal AM; Keith KC; Benbow JM; Shachar SS; Zagar T; Dees EC; Carey LA; Ewend MG; Anders CK
Clin Breast Cancer; 2018 Feb; 18(1):29-37. PubMed ID: 28867445
[TBL] [Abstract][Full Text] [Related]
16. Treatment patterns and survival in HER2-positive early breast cancer: a whole-of-population Australian cohort study (2007-2016).
Tang M; Schaffer A; Kiely BE; Daniels B; Simes RJ; Lee CK; Pearson SA
Br J Cancer; 2019 Nov; 121(11):904-911. PubMed ID: 31673103
[TBL] [Abstract][Full Text] [Related]
17. Relationship between tumor biomarkers and efficacy in MARIANNE, a phase III study of trastuzumab emtansine ± pertuzumab versus trastuzumab plus taxane in HER2-positive advanced breast cancer.
Perez EA; de Haas SL; Eiermann W; Barrios CH; Toi M; Im YH; Conte PF; Martin M; Pienkowski T; Pivot XB; Burris HA; Stanzel S; Patre M; Ellis PA
BMC Cancer; 2019 May; 19(1):517. PubMed ID: 31146717
[TBL] [Abstract][Full Text] [Related]
18. Clinical characteristics and disease outcomes in ER+ breast cancer: a comparison between HER2+ patients treated with trastuzumab and HER2- patients.
Li S; Wu J; Huang O; He J; Zhu L; Chen W; Li Y; Chen X; Shen K
BMC Cancer; 2021 Jul; 21(1):807. PubMed ID: 34256710
[TBL] [Abstract][Full Text] [Related]
19. The variation and clinical significance of hormone receptors and Her-2 status from primary to metastatic lesions in breast cancer patients.
Zhu YY; Si W; Ji TF; Guo XQ; Hu Y; Yang JL
Tumour Biol; 2016 Jun; 37(6):7675-84. PubMed ID: 26687919
[TBL] [Abstract][Full Text] [Related]
20. Gasdermin B expression predicts poor clinical outcome in HER2-positive breast cancer.
Hergueta-Redondo M; Sarrio D; Molina-Crespo Á; Vicario R; Bernadó-Morales C; Martínez L; Rojo-Sebastián A; Serra-Musach J; Mota A; Martínez-Ramírez Á; Castilla MÁ; González-Martin A; Pernas S; Cano A; Cortes J; Nuciforo PG; Peg V; Palacios J; Pujana MÁ; Arribas J; Moreno-Bueno G
Oncotarget; 2016 Aug; 7(35):56295-56308. PubMed ID: 27462779
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
